A Randomonized, Doulble- Blind Trial to Complare the Efficacy and Safety of Anastrozole (Arimidex 1 Mg daily) wtih Tomaxifen Citrate (20 mg daily) as First- Line Therapy for Advanced Breast Cancer in Post Menopausal Women

Study identifier:1033IL/0030

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomonized, Doulble- Blind Trial to Complare the Efficacy and Safety of Anastrozole (Arimidex 1 Mg daily) wtih Tomaxifen Citrate (20 mg daily) as First- Line Therapy for Advanced Breast Cancer in Post Menopausal Women

Medical condition

Breast Cancer

Phase

Phase 3

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Feb 1996

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2014&filename=CSR-1033IL-0030.pdf
Download
CSR-1033IL-0030.pdf
Download
Trial Results Summaries
Available here

A Randomonized, Doulble- Blind Trial to Complare the Efficacy and Safety of Anastrozole (Arimidex 1 Mg daily) wtih Tomaxifen Citrate (20 mg daily) as First- Line Therapy for Advanced Breast Cancer in Post Menopausal Women

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2014&filename=CSR-1033IL-0030.pdf

CSR-1033IL-0030.pdf

Trial Results Summaries